PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.06
D/E ratio at 50-90% of Healthcare median of 0.07. Peter Lynch would verify if this conservative capital structure supports growth opportunities.
7.35
Dangerously high net debt exceeding 1.5x Healthcare median of 1.12. Michael Burry would check for debt covenant compliance and refinancing risks.
-18.91
Negative coverage while Healthcare median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
9.21
Current ratio exceeding 1.5x Healthcare median of 2.59. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
No Data
No Data available this quarter, please select a different quarter.